What it's for (Indications)
- Trimethoprim is an antibiotic primarily indicated for the treatment of uncomplicated urinary tract infections (UTIs) caused by susceptible strains of bacteria.
- These commonly include Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae, and Enterobacter species.
- It is effective in both acute and recurrent UTIs.
- The clinical decision to use trimethoprim should be based on susceptibility testing when available, to ensure appropriate antimicrobial therapy and combat antimicrobial resistance.
- It may also be used in specific instances for other infections where bacterial susceptibility has been established, although its main therapeutic role remains in the management of urinary tract pathogens due to its excellent penetration into urinary tissues and fluids.
- This focused application minimizes off-target use and helps preserve its efficacy for its primary indications, contributing to responsible antibiotic stewardship in various healthcare settings, ensuring its judicious use against specific, proven susceptible organisms.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | For adults, the typical oral dosage of trimethoprim for the treatment of uncomplicated urinary tract infections is 100 mg administered every 12 hours, or 200 mg administered once daily, for a duration ranging from 3 to 10 days, depending on the severity of the infection and clinical response. In patients with renal impairment, dosage adjustments are crucial. For individuals with a creatinine clearance (CrCl) between 15 and 30 mL/min, the recommended dose is 50 mg every 12 hours. Trimethoprim is generally not recommended for patients with a CrCl less than 15 mL/min unless close monitoring of plasma concentrations and clinical effects is feasible. Pediatric dosing should be precisely calculated based on weight and age, adhering to established guidelines for optimal efficacy and safety. Always consult current prescribing information for specific dosage recommendations and adjustments, and consider local resistance patterns when selecting empirical therapy. |
Safety & Warnings
Common Side Effects
- Common side effects associated with trimethoprim therapy often involve the gastrointestinal system, including nausea, vomiting, abdominal discomfort, and diarrhea.
- Dermatological reactions are also relatively common, manifesting as rash, pruritus (itching), and photosensitivity.
- More serious, albeit less frequent, adverse effects include hematologic abnormalities such as megaloblastic anemia, leukopenia, neutropenia, and thrombocytopenia, particularly in individuals with pre-existing folate deficiency or those receiving prolonged high-dose therapy.
- Hyperkalemia can occur, especially in elderly patients, those with renal impairment, or individuals concurrently taking potassium-sparing diuretics, ACE inhibitors, or angiotensin receptor blockers.
- Hepatic dysfunction, characterized by elevated liver enzymes, has been reported.
- Severe skin reactions, including Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), although rare, represent serious hypersensitivity responses.
- Pseudomembranous colitis caused by Clostridioides difficile can also develop, requiring prompt recognition and management.
Serious Warnings
- Black Box Warning: **Serious Warnings** While trimethoprim alone does not carry an FDA-mandated Black Box Warning, several serious and potentially life-threatening adverse reactions warrant prominent consideration and careful patient monitoring. These include: * **Hematologic Toxicity:** Trimethoprim can lead to significant hematologic abnormalities due to its folate antagonist activity. These can manifest as megaloblastic anemia, leukopenia, neutropenia, and thrombocytopenia. This risk is particularly elevated in patients with pre-existing folate deficiency, the elderly, individuals with malnutrition, or those receiving high doses or prolonged courses of therapy. Complete blood counts should be routinely monitored, and trimethoprim should be discontinued if significant hematologic changes occur. Folinic acid supplementation may be considered in some high-risk cases to mitigate these effects. * **Hyperkalemia:** Clinically significant hyperkalemia has been observed with trimethoprim use, especially in patients with renal dysfunction, those receiving concomitant medications known to increase potassium levels (e.g., ACE inhibitors, ARBs, potassium-sparing diuretics), and the elderly. Fatalities due to hyperkalemia have been reported. Serum potassium levels should be closely monitored in at-risk patients, and appropriate interventions should be promptly initiated if hyperkalemia develops. * **Severe Dermatologic Reactions:** Serious and sometimes fatal dermatologic reactions, including Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), have been reported with trimethoprim. Patients should be advised to seek immediate medical attention at the first sign of a skin rash, blistering, or mucocutaneous lesions, and the drug should be promptly and permanently discontinued. * **Clostridioides difficile-Associated Diarrhea (CDAD):** Like many antibiotics, trimethoprim therapy can alter the normal flora of the colon, leading to the overgrowth of Clostridioides difficile. This can result in CDAD, which may range in severity from mild diarrhea to fatal colitis. CDAD should be considered in all patients presenting with diarrhea following antibiotic use, even several months after therapy, and appropriate diagnostic and therapeutic measures implemented.
- Patients receiving trimethoprim should be carefully monitored for potential adverse reactions.
- Particular caution is warranted in individuals with impaired renal function, as dose adjustments are necessary to prevent accumulation and toxicity, including hyperkalemia.
- Regular monitoring of serum potassium levels is recommended, especially in patients at increased risk, such as the elderly, those with kidney disease, or individuals on concomitant medications affecting potassium balance.
- Hematologic adverse effects, including megaloblastic anemia, leukopenia, and thrombocytopenia, can occur due to trimethoprim's folate antagonist activity.
- Therefore, complete blood counts should be performed periodically, especially during prolonged therapy or in patients with pre-existing folate deficiency.
- Severe dermatologic reactions, such as Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis, although rare, necessitate immediate discontinuation of the drug.
- Trimethoprim should be discontinued at the first appearance of skin rash or any sign of an adverse reaction.
- Pseudomembranous colitis, caused by Clostridioides difficile, has been reported with nearly all antibacterial agents, including trimethoprim, and may range in severity from mild to life-threatening, requiring appropriate management strategies.
How it Works (Mechanism of Action)
Trimethoprim exerts its bacteriostatic effect by selectively inhibiting bacterial dihydrofolate reductase (DHFR), an enzyme crucial for the synthesis of tetrahydrofolic acid. Tetrahydrofolic acid is a critical cofactor involved in the synthesis of purines, thymidine, and ultimately, bacterial DNA, RNA, and proteins. By competitively binding to and inhibiting DHFR, trimethoprim prevents the conversion of dihydrofolic acid to tetrahydrofolic acid within the bacterial cell. Mammalian dihydrofolate reductase is significantly less sensitive to trimethoprim, providing a basis for selective toxicity against bacterial pathogens. This interruption of the bacterial folate metabolic pathway effectively halts bacterial cell growth and replication, leading to its antimicrobial action. Its synergy with sulfamethoxazole in co-trimoxazole is due to blocking two sequential steps in the same metabolic pathway, but trimethoprim alone is potent enough for many susceptible infections, disrupting a vital bacterial metabolic process.
Commercial Brands (Alternatives)
No other brands found for this formula.